Key result
Low CYP3A4 activity is linked to higher stent thrombosis risk, unlike common CYP2C19 polymorphisms.
Why the study?
Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity increase the risk of stent implantation complications in ACS patients undergoing PCI?
Observational (n=76)
No
Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity increase the risk of stent implantation complications in ACS patients undergoing PCI?
Low CYP3A4 isoenzyme activity, but not CYP2C19 or ABCB1 polymorphisms, is associated with an increased risk of stent thrombosis in ACS patients undergoing PCI.
Answers are grounded in this paper and cite their sources.
CYP3A4 phenotyping may refine post-PCI thrombosis risk stratification in ACS; leaves open the value of CYP2C19 and ABCB1 genotyping.
Aim: The aim of this study was to determine the impact of CYP2C19 and ABCB1 gene polymorphisms and CYP3A4 isoenzyme activity on stent implantation complications among patients with an acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI). Patients and methods: Seventy-six patients (median age 63, range 37–91 years) with an ACS who underwent PCI were screened for CYP2C19 and ABCB1 gene polymorphisms with real-time polymerase chain reaction: CYP2C19*2 , CYP2C19*17 , and ABCB1 3435 . CYP3A4 isoenzyme activity was determined by urine cortisol and 6-beta-hydroxycortisol levels. Stent implantation complications such as stent thrombosis ( n =2) and restenosis ( n =1) were observed among drug-eluting stent recipients. Results: Low mean 6-beta-hydroxycortisol/cortisol ratio is indicative of impaired CYP3A4 activity and was associated with higher risk of thrombosis ( β coefficient=0.022, SE 0.009, p =0.021 in the linear regression model). The increase in the length of the implanted stent was associated with higher risk of restenosis ( β coefficient=0.006, SE=0.002, p =0.001 in the linear regression model). The presence of the CYP2C19*2 polymorphism did not affect the incidence of stent thrombosis ( β coefficient=−1.626, SE=1.449, p =0.262 in the logistic regression model), nor did the CYP2C19*17 ( β coefficient=−0.907, SE=1.438, p =0.528 in the logistic regression model) and ABCB1 3435 polymorphisms ( β coefficient=1.270, SE=1.442, p =0.378 in the logistic regression model). Conclusion: We did not find evidence that the presence of CYP2C19*2 , CYP2C19*17 , and ABCB1 3435 polymorphisms may jeopardize the safety of stent implantation in patients with an ACS. Patients with low CYP3A4 isoenzyme activity may have increased risk of stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Rytkin et al. (2017) conducted an observational in Acute coronary syndrome undergoing percutaneous coronary intervention (n=76). CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity vs. Wild-type carriers and normal CYP3A4 isoenzyme activity was evaluated on Stent thrombosis (beta coefficient 0.022 (SE 0.009), p=0.021). Low CYP3A4 isoenzyme activity was associated with a higher risk of stent thrombosis, whereas CYP2C19*2, CYP2C19*17, and ABCB1 3435 polymorphisms were not.
Synapse has enriched 10 related papers. Consider them for comparative context: